CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease

Intracranial atherosclerotic disease (ICAD) is responsible for 8-10% of acute ischemic strokes, and resistance to antiplatelet therapy is prevalent. CYP2C19 gene loss-of-function (up to 45% of patients) causes clopidogrel resistance. For patients with asymptomatic ICAD and ICAD characterized by transient ischemic attack (TIA), this study measures the effect of CYP2C19 loss-of-function on ischemic stroke risk during clopidogrel therapy.

https://www.strokejournal.org/article/S1052-3057(20)30882-X/fulltext?rss=yes

Source: Journal of Stroke and Cerebrovascular Diseases - November 24, 2020 Category: Neurology Authors: Pious D. Patel, Praveen Vimalathas, Xinnan Niu, Chevis N. Shannon, Joshua C. Denny, Josh F. Peterson, Rohan V. Chitale, Matthew R. Fusco Source Type: research